Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 159.9 Billion KRW | 10.82% |
| 2022 | 144.29 Billion KRW | 15.55% |
| 2021 | 124.88 Billion KRW | 7.79% |
| 2020 | 115.85 Billion KRW | 0.59% |
| 2019 | 115.18 Billion KRW | 21.86% |
| 2018 | 94.52 Billion KRW | 28.31% |
| 2017 | 73.66 Billion KRW | 6.81% |
| 2016 | 68.96 Billion KRW | 112.49% |
| 2015 | 32.45 Billion KRW | 18.75% |
| 2014 | 27.33 Billion KRW | 17.91% |
| 2013 | 23.18 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 42.67 Billion KRW | 24.86% |
| 2024 Q1 | 34.17 Billion KRW | -12.33% |
| 2023 FY | 159.9 Billion KRW | 10.82% |
| 2023 Q3 | 43.14 Billion KRW | 9.03% |
| 2023 Q1 | 38.2 Billion KRW | -11.83% |
| 2023 Q4 | 38.98 Billion KRW | -9.64% |
| 2023 Q2 | 39.57 Billion KRW | 3.58% |
| 2022 Q4 | 43.32 Billion KRW | 11.36% |
| 2022 FY | 144.29 Billion KRW | 15.55% |
| 2022 Q3 | 38.91 Billion KRW | 19.63% |
| 2022 Q2 | 32.52 Billion KRW | 10.14% |
| 2022 Q1 | 29.53 Billion KRW | -23.37% |
| 2021 FY | 124.88 Billion KRW | 7.79% |
| 2021 Q4 | 38.53 Billion KRW | 58.99% |
| 2021 Q2 | 31.45 Billion KRW | 2.65% |
| 2021 Q1 | 30.64 Billion KRW | -1.06% |
| 2021 Q3 | 24.23 Billion KRW | -22.94% |
| 2020 FY | 115.85 Billion KRW | 0.59% |
| 2020 Q1 | 25.22 Billion KRW | -43.04% |
| 2020 Q2 | 30.31 Billion KRW | 20.17% |
| 2020 Q3 | 29.33 Billion KRW | -3.24% |
| 2020 Q4 | 30.97 Billion KRW | 5.58% |
| 2019 Q3 | 20.7 Billion KRW | -15.27% |
| 2019 Q1 | 25.75 Billion KRW | 28.86% |
| 2019 FY | 115.18 Billion KRW | 21.86% |
| 2019 Q4 | 44.28 Billion KRW | 113.94% |
| 2019 Q2 | 24.43 Billion KRW | -5.15% |
| 2018 Q2 | 21.15 Billion KRW | -26.92% |
| 2018 FY | 94.52 Billion KRW | 28.31% |
| 2018 Q4 | 19.98 Billion KRW | -18.21% |
| 2018 Q3 | 24.44 Billion KRW | 15.55% |
| 2018 Q1 | 28.94 Billion KRW | 18.23% |
| 2017 FY | 73.66 Billion KRW | 6.81% |
| 2017 Q1 | 16.51 Billion KRW | -27.84% |
| 2017 Q2 | 17.41 Billion KRW | 5.45% |
| 2017 Q3 | 15.24 Billion KRW | -12.45% |
| 2017 Q4 | 24.48 Billion KRW | 60.53% |
| 2016 FY | 68.96 Billion KRW | 112.49% |
| 2016 Q4 | 22.89 Billion KRW | 112.57% |
| 2016 Q3 | 10.76 Billion KRW | -32.77% |
| 2016 Q2 | 16.01 Billion KRW | -16.98% |
| 2016 Q1 | 19.29 Billion KRW | 3.15% |
| 2015 Q3 | 3.4 Billion KRW | -31.29% |
| 2015 Q2 | 4.95 Billion KRW | -8.2% |
| 2015 Q1 | 5.39 Billion KRW | -48.66% |
| 2015 FY | 32.45 Billion KRW | 18.75% |
| 2015 Q4 | 18.7 Billion KRW | 449.57% |
| 2014 Q2 | 5.4 Billion KRW | -4.4% |
| 2014 Q1 | 5.65 Billion KRW | -23.43% |
| 2014 Q3 | 5.75 Billion KRW | 6.52% |
| 2014 Q4 | 10.51 Billion KRW | 82.49% |
| 2014 FY | 27.33 Billion KRW | 17.91% |
| 2013 Q4 | 7.38 Billion KRW | 97.72% |
| 2013 FY | 23.18 Billion KRW | 0.0% |
| 2013 Q2 | 6.71 Billion KRW | 25.83% |
| 2013 Q3 | 3.73 Billion KRW | -44.4% |
| 2013 Q1 | 5.33 Billion KRW | 0.0% |
| 2012 Q3 | 3.25 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| HLB Co., Ltd. | 42.9 Billion KRW | -272.732% |
| iNtRON Biotechnology, Inc. | 9.58 Billion KRW | -1568.199% |
| BINEX Co., Ltd. | 154.82 Billion KRW | -3.281% |
| Bioneer Corporation | 263.23 Billion KRW | 39.255% |
| Anterogen.Co.,Ltd. | 6.5 Billion KRW | -2359.972% |
| MEDIPOST Co., Ltd. | 68.64 Billion KRW | -132.951% |
| CrystalGenomics, Inc. | 4.87 Billion KRW | -3177.625% |
| Helixmith Co., Ltd | 4.2 Billion KRW | -3705.775% |
| Chabiotech Co.,Ltd. | 953.95 Billion KRW | 83.238% |
| Medy-Tox Inc. | 221.12 Billion KRW | 27.685% |
| Peptron, Inc. | 3.34 Billion KRW | -4684.841% |
| Genexine, Inc. | 4.42 Billion KRW | -3512.328% |
| HLB Therapeutics Co.,Ltd. | 53.74 Billion KRW | -197.502% |
| LegoChem Biosciences, Inc. | 34.14 Billion KRW | -368.301% |
| ALTEOGEN Inc. | 96.52 Billion KRW | -65.665% |
| PharmaResearch Co., Ltd. | 261.01 Billion KRW | 38.737% |
| SillaJen, Inc. | 3.93 Billion KRW | -3958.939% |
| JETEMA, Co., Ltd. | 58.71 Billion KRW | -172.335% |
| OliX Pharmaceuticals,Inc | 17.06 Billion KRW | -837.07% |
| Genomictree Inc. | 3.41 Billion KRW | -4578.287% |
| MedPacto, Inc. | - KRW | -Infinity% |
| D&D Pharmatech | 18.67 Billion KRW | -756.154% |
| EASY BIO,Inc. | 165.38 Billion KRW | 3.314% |
| GI Innovation, Inc. | 5.31 Billion KRW | -2906.37% |